Treatment Study of Soft Palatal Implants in Obstructive Sleep Apnea

This study has been completed.
Sponsor:
Collaborators:
Medtronic Xomed, Inc.
ResMed Foundation
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00263770
First received: December 7, 2005
Last updated: May 18, 2011
Last verified: May 2011

December 7, 2005
May 18, 2011
December 2005
October 2007   (final data collection date for primary outcome measure)
apnea-hypopnea index [ Time Frame: 90 days ] [ Designated as safety issue: No ]
apnea-hypopnea index
Complete list of historical versions of study NCT00263770 on ClinicalTrials.gov Archive Site
  • sleepiness [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • quality of life [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • ambulatory blood pressure [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • snoring [ Time Frame: 90 days ] [ Designated as safety issue: No ]
  • sleepiness
  • quality of life
  • ambulatory blood pressure
  • snoring
Not Provided
Not Provided
 
Treatment Study of Soft Palatal Implants in Obstructive Sleep Apnea
A Randomized, Controlled Treatment Trial of Soft Palatal Implants and Positive Airway Pressure in Mild to Moderate Obstructive Sleep Apnea and Snoring

The purpose of the study is to compare the effectiveness of soft palatal implants with placebo and continuous positive airway pressure treatment in obstructive sleep apnea.

Obstructive sleep apnea (OSA), frequently associated with disruptive snoring, is a prevalent disorder which is increasingly recognized by health care providers and lay people alike as an important factor in impaired daytime executive function as well as cardiovascular disease risk. Along with an increase in its recognition and diagnosis have come a growing pool of patients with milder disease and the associated challenge of ideal management. Positive airway pressure (PAP) is well established as the mainstay of treatment for OSA since it is effective at reversing daytime neurocognitive sequelae and may be a useful adjunct to therapy in those with cardiovascular disease coexisting with OSA. In patients with mild OSA, however, the response to PAP therapy appears muted, which is related in part to poor adherence to treatment. In response, a number of alternative treatments have evolved. The most recent innovation is soft palatal implants, which, in non-randomized, uncontrolled studies have demonstrated reasonable efficacy in the treatment of snoring and mild to moderate OSA. How the implants compare with standard therapy and their effect on cardiovascular variables are unknown. Because of the ease and rapidity with which this system is implanted, and because treatment effect is independent of patient compliance, there is high potential for widespread use in patients with milder OSA. We therefore are conducting a randomized, placebo-controlled clinical trial to compare the impact of palatal implants with PAP on sleep disordered breathing, daytime symptoms and blood pressure, as well as patient / bed partner acceptance.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Sleep Apnea, Obstructive
  • Device: soft palate implant
  • Other: Positive airway pressure (PAP)
    which is air delivered by a mask worn over the nose during sleep
  • Positive airway pressure (PAP)
    which is air delivered by a mask worn over the nose during sleep
    Intervention: Other: Positive airway pressure (PAP)
  • Active Comparator: outpatient surgical procedure
    where small fabric rods are inserted into the soft palate (the fleshy portion of the roof of the mouth) to stiffen the tissues.
    Intervention: Device: soft palate implant
  • Sham Comparator: Sham surgery
    an outpatient surgical procedure identical to #2 except that no rods are inserted into the soft palate.
    Intervention: Device: soft palate implant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64
October 2007
October 2007   (final data collection date for primary outcome measure)

INCLUSION CRITERIA

  1. Age >18 yrs
  2. AHI 5-30
  3. Tonsil size <50% of airway
  4. No anatomically fixed nasal stenosis
  5. BMI = 32 kg/m2 EXCLUSION CRITERIA

1. The presence of a concomitant untreated primary sleep disorder (restless legs syndrome, narcolepsy, idiopathic hypersomnia) 2. Severe daytime sleepiness (history of sleep-related motor vehicle or occupational accident) 3. Moderate to severe pulmonary disease (FEV1 <50% pred) 4. Neurologic impairment (h/o CVA, TIA, neuromuscular disease, diaphragmatic paralysis) 5. Significant cardiac disease (LVEF<50%, moderate to severe valvular disease) 6. Uncontrolled hypertension >180/110 7. Renal disease (Scr > 2.5) 8. Allergy to local anesthetics used for implantation procedure. 9. Pregnant or nursing women

Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00263770
1646-05, 5591559902
No
Sean M Caples, D.O, Mayo Clinic
Mayo Clinic
  • Medtronic Xomed, Inc.
  • ResMed Foundation
Principal Investigator: Sean M. Caples, D.O. Mayo Clinic
Mayo Clinic
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP